Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis

Experimental Cell Research

Volumn 330, Issue 1, 2015, Pages 1-12

  Belloni, Daniela ^a   Marcatti, Magda ^a   Ponzoni, Maurilio ^a   Ciceri, Fabio ^a   Veschini, Lorenzo ^a   Corti, Angelo ^a   Caligaris Cappio, Federico ^a,b   Ferrarini, Marina ^a   Ferrero, Elisabetta ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Angiogenesis; Angiopoietin 2; Bone Marrow microenvironment; Endothelial cells; Multiple Myeloma

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; VASCULOTROPIN; ANGIOPOIETIN RECEPTOR; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BONE MARROW; CANCER PATIENT; CAPILLARY DENSITY; CELL ACTIVATION; CELL MEMBRANE PERMEABILITY; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MALE; MONOCYTE; MULTIPLE MYELOMA; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPOIETIN-1; ANGIOPOIETIN-2; BONE MARROW; CASE-CONTROL STUDIES; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, TIE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84916886858     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.10.017     Document Type: Article

References (49)

1. Belloni D., Scabini S., Foglieni C., Veschini L., Giazzon A., Colombo B., Fulgenzi A., Helle K.B., Ferrero M.E., Corti A., Ferrero E. The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration. FASEB J. 2007, 21:3052-3062.
2. Belloni D., Veschini L., Foglieni C., Dell'Antonio G., Caligaris-Cappio F., Ferrarini M., Ferrero E. Bortezomib induces autophagic death in proliferating human endothelial cells. Exp. Cell Res. 2010, 316:1010-1018.
3. Berardi S., Ria R., Reale A., De Luisi A., Catacchio I., Moschetta M., Vacca A. Multiple myeloma macrophages: pivotal players in the tumor microenvironment. J. Oncol. 2013, 2013:183602.
4. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
5. Burger J.A., Ghia P., Rosenwald A., Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009, 114:3367-3375.
6. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
7. Cascone T., Heymach J.V. Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?. J. Clin. Oncol. 2012, 30:441-444.
8. Colla S., Storti P., Donofrio G., Todoert K., Bolzoni M., Lazzaretti M., Abeltino M., Ippolito L., Neri A., Ribatti D., Rizzoli V., Martella E., Giuliani N Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia 2010, 24:1967-1970.
9. Eklund L., Olsen B.R. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp. Cell Res. 2006, 312:630-641.
10. Eklund L., Saharinen P Angiopoietin signaling in the vasculature. Exp. Cell Res. 2013, 319:1271-1280.
11. Ferrarini M., Ferrero E Proteasome inhibitors and modulators of angiogenesis in multiple myeloma. Curr. Med. Chem. 2011, 18:5185-5195.
12. Ferrarini M., Steimberg N., Ponzoni M., Belloni D., Berenzi A., Girlanda S, Caligaris-Cappio F., Mazzoleni G., Ferrero E. Ex-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of multiple myeloma biology and response to therapy. PLoS One 2013, 8:e71613.
13. Fiedler U., Scharpfenecker M., Koidl S., Hegen A., Grunow V., Schmidt J.M. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004, 103:4150-4156.
14. Fiedler U., Augustin H.G. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol. 2006, 27:552-558.
15. Fukuhara S., Sako K., Minami T., Noda K., Kim H.Z., Kodama T., Shibuya M., Takakura N., Koh G.Y., Mochizuki N. Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat. Cell Biol. 2008, 10:513-526.
16. Fukuhara S., Sako K., Noda K., Nagao K., Miura K., Mochizuki N. Tie2 is tied at the cell-cell contacts and to extracellular matrix by angiopoietin-1. Exp. Mol. Med. 2009, 41:133-139.
17. Gerald D., Chintharlapalli S., Augustin H.G., Benjamin L.E. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res. 2013, 73:1649-1657.
18. Giuliani N., Colla S., Lazzaretti M., Sala R., Roti G., Mancini C., Bonomini S., Lunghi P., Hojden M., Genestreti G., Svaldi M., Coser P., Fattori P.P., Sammarelli G., Gazzola G.C, Bataille R., Almici C., Caramatti C., Mangoni L., Rizzoli V. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 2003, 102:638-645.
19. Hallek M., Bergsagel P.L., Anderson K.C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998, 91:3-21.
20. Hideshima T., Mitsiades C., Tonon G., Richardson P.G., Anderson K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer 2007, 7:585-598.
21. Huang H., Bhat A., Woodnutt G., Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat. Rev. Cancer 2010, 10:575-585.
22. Hussein M.A., Juturi J.V., Lieberman I. Multiple myeloma: present and future. Curr. Opin. Oncol. 2002, 14:31-35.
23. Jakob C., Sterz J., Zavrski I., Heider U, Kleeberg L., Fleissner C., Kaiser M., Sezer O. Angiogenesis in multiple myeloma. Eur. J. Cancer 2006, 42:1581-1590.
24. Joshi S., Khan R., Sharma M., Kumar L., Sharma A. Angiopoietin-2: a potential novel diagnostic marker in multiple myeloma. Clin. Biochem. 2011, 44:590-595.
25. Kumar S., Witzig T.E., Timm M., Haug J., Wellik L., Kimlinger T.K., Greipp P.R., Rajkumar S.V. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004, 104:1159-1165.
26. Maffei R., Martinelli S., Santachiara R., Rossi D., Guarnotta C., Sozzi E., Zucchetto A., Rigolin G.M., Fiorcari S., Castelli I., Fontana M., Coluccio V., Leonardi G., Zucchini P., Tripodo C., Cuneo A., Gattei V., Del Poeta G., Forconi F., Gaidano G., Torelli G., Marasca R. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. Blood 2010, 116:584-592.
27. Maffei R., Martinelli S., Castelli I., Santachiara R., Zucchini P., Fontana M., Fiorcari S., Bonacorsi G., Ilariucci F., Torelli G., Marasca R. Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. Leuk. Res. 2010, 34:312-321.
28. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., Compton D., McClain J., Aldrich T.H, Papadopoulos N., Daly T.J., Davis S., Sato T.N., Yancopoulos GD. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
29. Moschetta M., Di Pietro G., Ria R., Gnoni A., Mangialardi G., Guarini A., Ditonno P., Musto P., D'Auria F., Ricciardi M.R., Dammacco F., Ribatti D., Vacca A. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur. J. Cancer 2010, 46:420-429.
30. Moserle L., Amadori A., Indraccolo S. The angiogenic switch: implications in the regulation of tumor dormancy. Curr. Mol. Med. 2009, 9:935-941.
31. Nerini-Molteni S., Ferrarini M., Cozza S., Caligaris-Cappio F., Sitia R. Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. Br. J. Haematol. 2008, 141:494-503.
32. Oubaha M., Lin M.I., Margaron Y., Filion D., Price E.N., Zon L.I., CÔté J.F., Gratton JP. Formation of a PKCζ/β-catenin complex in endothelial cells promotes angiopoietin-1-induced collective directional migration and angiogenic sprouting. Blood 2012, 120:3371-3381.
33. Pappa C.A., Tsirakis G., Samiotakis P., Tsigaridaki M., Alegakis A., Goulidaki N., Alexandrakis M.G. Serum levels of angiopoietin-2 are associated with the growth of multiple myeloma. Cancer Investig. 2013, 31:385-389.
34. Peters K.G. Vascular endothelial growth factor and the angiopoietins: working together to build a better blood vessel. Circ. Res. 1998, 83:342-343.
35. Pichiule P., Chavez J.C., LaManna J.C. Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J. Biol. Chem. 2004, 279:12171-12180.
36. Pruneri G., Ponzoni M., Ferreri A.J., Decarli N., Tresoldi M., Raggi F., Baldessari C., Freschi M., Baldini L., Goldaniga M., Neri A., Carboni N., Bertolini F., Viale G. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br. J. Haematol. 2002, 118:817-820.
37. Ramanujan S., Koenig G.C., Padera T.P., Stoll B.R, Jain R.K. Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors. Cancer Res. 2000, 60:1442-1448.
38. Ribatti D., Nico B., Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006, 25:4257-4266.
39. Ribatti D., Mangialardi G., Vacca A. Antiangiogenic therapeutic approaches in multiple myeloma. Curr. Cancer Drug Targ. 2012, 12:768-775.
40. Saharinen P., Eklund L., Miettinen J., Wirkkala R., Anisimov A., Winderlich M., Nottebaum A., Vestweber D., Deutsch U., Koh G.Y., Olsen B.R., Alitalo K. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat. Cell Biol. 2008, 10:527-537.
41. Scavelli C., Nico B., Cirulli T., Ria R., Di Pietro G., Mangieri D., Bacigalupo A., Mangialardi G., Coluccia A.M., Caravita T., Molica S., Ribatti D., Dammacco F., Vacca A. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene 2008, 24(27):663-674.
42. Shim W.S., Ho I.A., Wong PE. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol. Cancer Res. 2007, 5:655-665.
43. Terpos E., Anargyrou K., Katodritou E., Kastritis E., Papatheodorou A., Christoulas D., Pouli A., Michalis E., Delimpasi S., Gkotzamanidou M., Nikitas N., Koumoustiotis V., Margaritis D., Tsionos K., Stefanoudaki E., Meletis J., Zervas K., Dimopoulos M.A. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. Int. J. Cancer 2012, 130:735-742. Greek Myeloma Study Group, Greece.
44. Thurston G., Daly C. The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway. Cold Spring Harb. Perspect. Med. 2012, 2(9):a006550.
45. Uneda S., Matsuno F., Sonoki T., Tniguchi I., Kawano F., Hata H. Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cells. Haematologica 2003, 88:113-115.
46. Vacca A., Ria R., Semeraro F., Merchionne F., Coluccia M., Boccarelli A. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood 2003, 102:3340-3348.
47. Vacca A., Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia 2006, 20:193-199.
48. Veschini L., Belloni D., Foglieni C., Cangi M.G., Ferrarini M., Caligaris-Cappio F., Ferrero E. Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. Blood 2007, 109:2565-2570.
49. Yuan H.T., Khankin E.V., Karumanchi S.A., Parikh S.M. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol. Cell Biol. 2009, 29:2011-2022.